Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
London.
Matthew
M
Limb
D000047:Academies and Institutes; D003365:Costs and Cost Analysis; D003695:Delivery of Health Care; D004345:Drug Industry; D004364:Pharmaceutical Preparations / Q000191:economics*; D006113:United Kingdom
D004364:Pharmaceutical Preparations